Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer SH, Kimeswenger S, Oellinger A, Forschner A, Leiter U, Weide B, Gassenmaier M, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen VA, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Eigentler TK. Wagner NB, et al. Among authors: gebhardt c. J Immunother Cancer. 2021 May;9(5):e002350. doi: 10.1136/jitc-2021-002350. J Immunother Cancer. 2021. PMID: 33986126 Free PMC article.
Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.
Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J, Ikenberg K, Busch C, Holland-Letz T, Naeher H, Garbe C, Umansky V, Enk A, Utikal J, Gebhardt C. Wagner NB, et al. Among authors: gebhardt c. Int J Cancer. 2015 Dec 1;137(11):2607-17. doi: 10.1002/ijc.29619. Epub 2015 Jul 14. Int J Cancer. 2015. PMID: 26018980 Free article.
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kähler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD. Weide B, et al. Among authors: gebhardt c. Clin Cancer Res. 2016 Nov 15;22(22):5487-5496. doi: 10.1158/1078-0432.CCR-16-0127. Epub 2016 May 16. Clin Cancer Res. 2016. PMID: 27185375 Free PMC article.
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, Gesierich A, Gutzmer R, Kähler KC, Livingstone E, Diamantopoulos PT, Gogas H, Madonna G, Ascierto PA, Goldinger SM, Mangana J, Garbe C, Schadendorf D, Blank C, Weide B. Schilling B, et al. Among authors: gebhardt c. Cancer Immunol Immunother. 2019 May;68(5):765-772. doi: 10.1007/s00262-019-02311-1. Epub 2019 Feb 26. Cancer Immunol Immunother. 2019. PMID: 30806748 Free PMC article.
Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies.
Wagner NB, Weide B, Gries M, Reith M, Tarnanidis K, Schuermans V, Kemper C, Kehrel C, Funder A, Lichtenberger R, Sucker A, Herpel E, Holland-Letz T, Schadendorf D, Garbe C, Umansky V, Utikal J, Gebhardt C. Wagner NB, et al. Among authors: gebhardt c. J Immunother Cancer. 2019 Dec 5;7(1):343. doi: 10.1186/s40425-019-0828-1. J Immunother Cancer. 2019. PMID: 31806053 Free PMC article.
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG).
Steeb T, Wessely A, Alter M, Bayerl C, Bender A, Bruning G, Dabrowski E, Debus D, Devereux N, Dippel E, Drexler K, Dücker P, Dummer R, Emmert S, Elsner P, Enk A, Gebhardt C, Gesierich A, Goebeler M, Goerdt S, Goetze S, Gutzmer R, Haferkamp S, Hansel G, Hassel JC, Heinzerling L, Kähler KC, Kaume KM, Krapf W, Kreuzberg N, Lehmann P, Livingstone E, Löffler H, Loquai C, Mauch C, Mangana J, Meier F, Meissner M, Moritz RKC, Maul LV, Müller V, Mohr P, Navarini A, Van Nguyen A, Pfeiffer C, Pföhler C, Posch C, Richtig E, Rompel R, Sachse MM, Sauder S, Schadendorf D, Schatton K, Schulze HJ, Schultz E, Schilling B, Schmuth M, Simon JC, Streit M, Terheyden P, Thiem A, Tüting T, Welzel J, Weyandt G, Wesselmann U, Wollina U, Ziemer M, Zimmer L, Zutt M, Berking C, Schlaak M, Heppt MV; German Dermatologic Cooperative Oncology Group (DeCOG, committee ocular melanoma). Steeb T, et al. Among authors: gebhardt c. J Cancer Res Clin Oncol. 2021 Jun;147(6):1763-1771. doi: 10.1007/s00432-020-03450-0. Epub 2020 Nov 21. J Cancer Res Clin Oncol. 2021. PMID: 33219855 Free PMC article.
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients.
Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, Kähler K, Schilling B, Loquai C, Berking C, Hüning S, Schatton K, Gebhardt C, Eckardt J, Gutzmer R, Reinhardt L, Glutsch V, Nikfarjam U, Erdmann M, Stang A, Kowall B, Roesch A, Ugurel S, Zimmer L, Schadendorf D, Livingstone E. Lodde G, et al. Among authors: gebhardt c. Cancers (Basel). 2021 May 12;13(10):2319. doi: 10.3390/cancers13102319. Cancers (Basel). 2021. PMID: 34065995 Free PMC article.
Adjuvant pembrolizumab-related hyperprogression in stage III melanoma.
Ammann NL, Geidel G, Schneider SW, Gebhardt C. Ammann NL, et al. Among authors: gebhardt c. J Dtsch Dermatol Ges. 2021 Sep;19(9):1341-1345. doi: 10.1111/ddg.14535. Epub 2021 Jul 13. J Dtsch Dermatol Ges. 2021. PMID: 34255418 No abstract available.
492 results